Factors Affecting the Price of Cyramza
Cyramza (ramucirumab)’s price is shaped by multiple factors.
Factors Affecting the Price of Cyramza
High R&D costs for developing this VEGF receptor antagonist and conducting clinical trials for various cancers (e.g., gastric, lung) are a major driver. Patent exclusivity allows Eli Lilly to maintain market dominance, enabling premium pricing.
Production complexities, such as biologic manufacturing and strict quality control, inflate costs. Market demand for anti-angiogenic therapies in advanced cancers and regional healthcare policies (e.g., insurance coverage) also influence patient out-of-pocket expenses.
